ImPact Biotech appointed new leadership in 2020 to drive the next exciting phase of development of the Padeliporfin VTP oncology platform, starting with the lead indication in Upper Tract Urothelial Cancer (UTUC).

Our industry leading partnerships are accelerating our program in several indications. As we progress our clinical program we will continue to build our partnerships, manufacturing, and team required to bring Padeliporfin VTP to patients worldwide. From our technology roots in Israel, we strive to become the leading global biotechnology company in Photodynamic Therapy.

Impact Biotech is honoured to have received a prestigious grant from the European Innovation Council’s (EIC) Accelerator program, affirming the innovative merit and scientific potential of our technology.
This recognition serves as an important milestone, propels us forward, fuelling our mission to deliver cutting-edge therapy that can reshape the future of healthcare, and enabling us to advance our development efforts with increased rigor and impact for the benefit of patients.